Determination of ADAMTS13 and Its Clinical Significance for ADAMTS13 Supplementation Therapy to Improve the Survival of Patients with Decompensated Liver Cirrhosis
Figure 3
Relationship of ADAMTS13 : AC to the presence or absence of hepatic encephalopathy, hepatorenal syndrome, and ascites in patients with liver cirrhosis. The ADAMTS13 : AC was significantly lower in LC patients with hepatic encephalopathy (a) and hepatorenal syndrome (b) than that those without. Moreover, patients with refractory ascites had lower ADAMTS13 : AC than those without ascites or those with easily mobilized ascites (c). Closed circles indicate patients whose plasma ADAMTS13 : AC was extremely low (< 3% of normal control by VWFM assay). ADAMTS13 : AC: ADAMTS13 activity; * significantly different between the two groups. (Partially modified from Uemura et al., [30]).
